BACKGROUND: Standard treatment for highly advanced gastric cancer (AGC) has not been established yet. Neoadjuvant chemotherapy (NAC) represents a promising approach, which may improve the prognosis of AGC. In this study, we analyzed the feasibility and efficacy of NAC with S-1 (TS-1)/cisplatin CDDP in order to design appropriate clinical trials for AGC. METHODS: Results for a series of 45 consecutive patients with AGC treated with S-1/CDDP induction chemotherapy since January 2002 were analyzed retrospectively. RESULTS: The primary tumor was resected in 36 of the 45 patients (resectability, 80.0%). Progression of the disease during chemotherapy was observed in 1 patient only (2.2%). No treatment-related deaths occurred, and serious adverse effects (grade 3-4) were noted in only 2.2% of the patients. The overall median survival time was 1.82 years. Especially noteworthy is that, in patients with highly advanced disease (pretreatment [c]-stage IV; n = 27), resectability was 66.7% and curative (R0) resection was possible in 10 patients. The median survival times for c-stage IV patients who had total, curative, and noncurative resections were 20.8, 22.3 and 12.6 months, respectively. R0 resection was possible for all c-stage III patients (n = 17), with a 2-year overall survival of 90.9%. The downstaging rate was 55.6% (20/36), resulting in a significantly improved prognosis for the downstaged patients (P = 0.012). CONCLUSION: Induction chemotherapy using S-1/CDDP for AGC appears to be a safe and promising treatment. We have therefore started two independent multiinstitutional clinical trials to evaluate the efficacy of this treatment.
BACKGROUND: Standard treatment for highly advanced gastric cancer (AGC) has not been established yet. Neoadjuvant chemotherapy (NAC) represents a promising approach, which may improve the prognosis of AGC. In this study, we analyzed the feasibility and efficacy of NAC with S-1 (TS-1)/cisplatin CDDP in order to design appropriate clinical trials for AGC. METHODS: Results for a series of 45 consecutive patients with AGC treated with S-1/CDDP induction chemotherapy since January 2002 were analyzed retrospectively. RESULTS: The primary tumor was resected in 36 of the 45 patients (resectability, 80.0%). Progression of the disease during chemotherapy was observed in 1 patient only (2.2%). No treatment-related deaths occurred, and serious adverse effects (grade 3-4) were noted in only 2.2% of the patients. The overall median survival time was 1.82 years. Especially noteworthy is that, in patients with highly advanced disease (pretreatment [c]-stage IV; n = 27), resectability was 66.7% and curative (R0) resection was possible in 10 patients. The median survival times for c-stage IV patients who had total, curative, and noncurative resections were 20.8, 22.3 and 12.6 months, respectively. R0 resection was possible for all c-stage III patients (n = 17), with a 2-year overall survival of 90.9%. The downstaging rate was 55.6% (20/36), resulting in a significantly improved prognosis for the downstaged patients (P = 0.012). CONCLUSION: Induction chemotherapy using S-1/CDDP for AGC appears to be a safe and promising treatment. We have therefore started two independent multiinstitutional clinical trials to evaluate the efficacy of this treatment.
Authors: E Mari; I Floriani; A Tinazzi; A Buda; M Belfiglio; M Valentini; S Cascinu; S Barni; R Labianca; V Torri Journal: Ann Oncol Date: 2000-07 Impact factor: 32.976
Authors: I Songun; H J Keizer; J Hermans; P Klementschitsch; J E de Vries; J A Wils; J van der Bijl; J H van Krieken; C J van de Velde Journal: Eur J Cancer Date: 1999-04 Impact factor: 9.162
Authors: J A Ajani; P F Mansfield; P M Lynch; P W Pisters; B Feig; P Dumas; D B Evans; I Raijman; K Hargraves; S Curley; D M Ota Journal: J Clin Oncol Date: 1999-08 Impact factor: 44.544
Authors: Y Yonemura; T Sawa; K Kinoshita; N Matsuki; S Fushida; S Tanaka; S Ohoyama; T Takashima; H Kimura; T Kamata Journal: World J Surg Date: 1993 Mar-Apr Impact factor: 3.352
Authors: P Chollet; S Amat; H Cure; M de Latour; G Le Bouedec; M-A Mouret-Reynier; J-P Ferriere; J-L Achard; J Dauplat; F Penault-Llorca Journal: Br J Cancer Date: 2002-04-08 Impact factor: 7.640
Authors: E Mochiki; K Ogata; T Ohno; Y Toyomasu; N Haga; Y Fukai; R Aihara; H Ando; N Uchida; T Asao; H Kuwano Journal: Br J Cancer Date: 2012-05-22 Impact factor: 7.640